Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Padsevonil in Hepatic Impairment
NCT04136444Phase 1Terminated
- Sponsor
- UCB
- Start
- Oct 2019
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of padsevonil in focal onset seizure (2 arms), sponsored by UCB. Primary endpoints: Maximum Plasma Concentration of a Single Dose Padsevonil, Area Under the Plasma Concentration-time Curve From Time 0 to t of a Single Dose Padsevonil and 3 more. Started Oct 2019; status: terminated.
02
Drugs
padsevonil
03
Conditions
focal onset seizure
Beyond the preview
Go deeper on NCT04136444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04136444.